4basebio
Amy Walker is an accomplished professional with extensive experience in the biotechnology sector. Currently serving as Chief Operating Officer at 4basebio since November 2020, Amy has also held the positions of Vice President of Research and Business Development, Director of Discovery, and Head of Discovery within the same company. Prior to 4basebio, Amy was a Post Doctoral Researcher at University College London from November 2019 to November 2020. Amy Walker holds a Doctor of Philosophy (PhD) in Gene Editing for Cystic Fibrosis from University College London, as well as a Master of Research in Biomedical Science and Translational Medicine, and a Bachelor of Science with Honours in Pharmacology, both from the University of Liverpool.
This person is not in any teams
4basebio
4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.